___

• Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009; 6:e1000114. doi: 10.1371/journal.pmed.1000114.
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:359- 86. doi: 10.1002/ijc.29210.
• Landrum LM, Java J, Mathews CA, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2013; 130:12-8. doi: 10.1016/j. ygyno.2013.04.001.
• Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354(1):34-43. doi: 10.1056/NEJMoa052985.
• Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2015; 33:1460-6. doi: 10.1200/jco.2014.55.9898.
• Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:1001-7. doi: 10.1200/jco.2001.19.4.1001.
• Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 2007; 17:1-20. doi: 10.1111/j.1525-1438.2007.00809.x.
• National Cancer Institute. NCI clinical announcement in 2006: intraperitoneal chemotherapy for ovarian cancer Available from: [http://ctepcancergov/highlights/docs/clin_ annc_010506pdf]; Accessed 30/11/2017.
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982; 5:649- 56.
• Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82:359-74.
• Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335:1950-5. doi: 10.1056/nejm199612263352603.
• Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 2006; 24:988-94. doi: 10.1200/ jco.2005.05.2456.
• Lesnock JL, Richard SD, Zorn KK, et al. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. Gynecol Oncol 2010; 116:345-50. doi: 10.1016/j.ygyno.2009.11.009.
• Berry E, Matthews KS, Singh DK, et al. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol 2009; 113:63-7. doi: 10.1016/j. ygyno.2008.12.035.
• Helm CW. Ports and complications for intraperitoneal chemotherapy delivery. BJOG 2012; 119:150-9. doi: 10.1111/j.1471-0528.2011.03179.x.
• Speyer JL, Myers CE. The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res 1980; 74:264-9.
• Pfeifle CE, Howell SB, Markman M, Lucas WE. Totally implantable system for peritoneal access. J Clin Oncol 1984; 2:1277-80. doi: 10.1200/jco.1984.2.11.1277.
• Black D, Levine DA, Nicoll L, et al. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol 2008; 109:39-42. doi: 10.1016/j.ygyno.2007.12.004.
• Varney RR, Goel R, vanSonnenberg E, Lucas WE, Casola G. Delayed erosion of intraperitoneal chemotherapy catheters into the bowel. Report of two cases. Cancer 1989; 64:762-4.
• Emoto S, Ishigami H, Hidemura A, et al. Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Jpn J Clin Oncol 2012; 42:1013- 9. doi: 10.1093/jjco/hys129.
• Ivy JJ, Geller M, Pierson SM, Jonson AL, Argenta PA. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution’s experience. Gynecol Oncol 2009; 114:420-3. doi: 10.1016/j.ygyno.2009.05.036.
• Landrum LM, Gold MA, Moore KN, Myers TK, McMeekin DS, Walker JL. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol 2008; 108:342-7. doi: 10.1016/j.ygyno.2007.10.004.
• Davidson SA, Rubin SC, Markman M, et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol 1991; 41:101-6.
• Sakuragi N, Nakajima A, Nomura E, et al. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma. Gynecol Oncol 2000; 79:420-3. doi: 10.1006/gyno.2000.5979.
• Nanninga AG, Willemse PH, Boonstra H, De Vries EG. Low complication rate during intraperitoneal therapy through a totally implanted peritoneal access port in patients with ovarian cancer. Int J Gynecol Cancer 1992; 2:107-10.
• Topuz E, Salihoglu Y, Aydiner A, et al. Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer. J Surg Oncol 2000; 74:223-6.
• Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2006; 100:27-32. doi: 10.1016/j. ygyno.2005.11.013.
• Pendergrass M, Gordinier ME, Parker LP, Metzinger DS, Helm CW. Retraction of an intraperitoneal chemotherapy port: a case report and literature review. Int J Gynecol Cancer 2007; 17:1131-3. doi: 10.1111/j.1525-1438.2007.00910.x.
• Piccart MJ, Speyer JL, Markman M, et al. Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol 1985; 12(3 Suppl 4):90-6.